Patient Engagement Helps Nexavar Secure Scottish Reimbursement For Liver Cancer
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium (SMC), the HTA body for Scotland, has accepted five new medicines for routine use by NHS Scotland. Two of these medicines, sorafenib (Bayer's Nexavar) for hepatocellular carcinoma (liver cancer) and tolvaptan (Otsuka's Jinarc) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) were accepted after consideration under SMC's PACE (Patient and Clinician Engagement) process.